 Comparisons with AGIO are from hundreds of biotech product developers viewed continually by institutional investors as capital gain sources. Values are based on how market professionals protect their own capital, put at risk in order to fill multi-million- trade orders placed by institutions managing multi-Billion- portfolios. 